The main obstacle has been the intolerant adverse effects such as hepatotoxicity, fatigue, nausea, diarrhea, myalgias, and retinal dysfunction, leading to a plausible notion that HSP90 may not be a viable anti-cancer target [263,264]. This evidence concerns the gene HSP90AB1 and cancer.